Report cover image

Implantable Cardioverter Defibrillators (ICD) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022

Publisher GlobalData
Published Mar 17, 2022
Length 93 Pages
SKU # GBDT17166092

Description

Implantable Cardioverter Defibrillators (ICD) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022

Summary

GlobalData's Medical Devices sector report, “Implantable Cardioverter Defibrillators (ICD) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 provides comprehensive information about the Implantable Cardioverter Defibrillators (ICD) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

An implantable cardioverter defibrillator (ICD) is an electronic device that monitors the heart’s rhythm and delivers electric pulses if it detects an arrhythmia (irregular heartbeat) to restore the heart’s natural rhythm.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Implantable Cardioverter Defibrillators (ICD) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Implantable Cardioverter Defibrillators (ICD) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to Buy

The report enables you to

Formulate significant competitor information, analysis, and insights to improve R&D strategies- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage- Identify and understand important and diverse types of Implantable Cardioverter Defibrillators (ICD) under development- Develop market-entry and market expansion strategies- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline- In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Contents

93 Pages
  • About GlobalData
    • Implantable Cardioverter Defibrillators (ICD) Overview
    • Implantable Cardioverter Defibrillators (ICD) - Pipeline Products by Stage of Development
    • Implantable Cardioverter Defibrillators (ICD) - Pipeline Products by Segment
    • Implantable Cardioverter Defibrillators (ICD) - Pipeline Products by Territory
    • Implantable Cardioverter Defibrillators (ICD) - Pipeline Products by Regulatory Path
    • Implantable Cardioverter Defibrillators (ICD) - Pipeline Products by Estimated Approval Date
    • Implantable Cardioverter Defibrillators (ICD) - Ongoing Clinical Trials
    • Implantable Cardioverter Defibrillators (ICD) Companies - Pipeline Products by Stage of Development
    • Implantable Cardioverter Defibrillators (ICD) –Companies Pipeline Products by Stage of Development
    • Advanced BioInformatics GmbH Company Overview
    • AIS Inc. Company Overview
    • Arrhythmia Dynamics LLC Company Overview
    • Boston Scientific Corp Company Overview
    • CardiaLen, Inc. Company Overview
    • Coridea, LLC Company Overview
    • InnerPulse Inc (Inactive) Company Overview
    • Johns Hopkins University Company Overview
    • Kenergy Inc. Company Overview
    • Massachusetts General Hospital Company Overview
    • Max Planck Institute for Dynamics and Self-Organization Company Overview
    • Medicool Technologies Inc Company Overview
    • Medtronic Inc Company Overview
    • Medtronic Plc Company Overview
    • MicroPort CRM SA Company Overview
    • MicroPort Scientific Corp Company Overview
    • Smartwave Medical Ltd (Inactive) Company Overview
    • University of Chicago Company Overview
    • Feb 08, 2022: JMS Announces Financial Results for the 3rd Quarter of FYE March 2022
    • Feb 02, 2022: Nihon Kohden Announces Revisions to its Forecast for Financial Results and Dividend
    • Feb 02, 2022: Nihon Kohden announces FY2021 third quarter consolidated financial results
    • Jan 31, 2022: Fukuda Denshi Co. Announces Financial Results for the Third Quarter of the Fiscal Year Ending March 2022
    • Jan 28, 2022: Japan Lifeline Co. Announces Consolidated Financial Results for the Nine months Ended December 31, 2021
    • Jan 26, 2022: CONMED Announces Fourth Quarter and Full-Year 2021 Financial Results
    • Jan 24, 2022: Philips announces Q4 and annual results 2021
    • Jan 19, 2022: Philips supports the American Heart Association’s efforts to raise awareness of cardiovascular implantable electronic device (CIED) infections, promote guideline adherence, and improve patient survival rates
    • Jan 04, 2022: Medtronic Chairman and CEO Geoff Martha to speak at J.P. Morgan healthcare conference
    • Nov 26, 2021: About 12 percent of patients who fill an opioid prescription after common cardiac implants develop persistent opioid use
    • Nov 12, 2021: Shree Pacetronix Announces Unaudited Financial Results For The Quarter And Half Year Ended 30Th September, 2021
    • Nov 08, 2021: Nihon Kohden Announces a Revision to its Forecast for Financial Results
    • Nov 08, 2021: Nihon Kohden announces FY2021 second quarter consolidated financial results
    • Nov 08, 2021: Boston Scientific Announces Upcoming Conference Schedule
    • Nov 05, 2021: JMS Announces Financial Results for the Second Quarter of Fiscal Year Ending March 31, 2022
    • Nov 01, 2021: Japan Lifeline Announces FY3/2022 2Q Financial Results
    • Oct 29, 2021: Fukuda Denshi announces Financial Results for the Second Quarter of the Fiscal Year Ending March 2022
    • Oct 27, 2021: Boston Scientific Announces Results For Third Quarter 2021
    • Oct 27, 2021: CONMED Announces Third Quarter Financial Results
    • Sep 14, 2021: Nihon Kohden announces a revision to its forecast for financial results for the first half of the fiscal year ending March 31, 2022
    • Sep 09, 2021: Boston Scientific Announces 2021 Investor Day Meeting
    • Aug 09, 2021: American Medical Association issues new category III CPT code for ZOLL Medical’s TherOx SSO2 therapy
    • Aug 06, 2021: JMS Announces Financial Results for the First Quarter of Fiscal Year Ending March 31, 2022
    • Aug 04, 2021: Nihon Kohden Announces a Revision to its Forecast for Financial Results
    • Aug 04, 2021: Nihon Kohden Announces Consolidated Financial Results for the 1st Quarter of the Fiscal Year Ending March 31, 2022
    • Aug 04, 2021: Japan Lifeline Announces FY3/2022 1Q Financial Results
    • Jul 30, 2021: Fukuda Denshi Co. Announces Financial Results for the First Quarter of the Fiscal Year Ending March 2022
    • Jul 30, 2021: Fukuda Denshi Notice Regarding Business Forecast and Dividend Forecast for the Fiscal Year Ending March 2022
    • Jul 28, 2021: CONMED Announces financial results for the second quarter ended June 30, 2021
    • Jul 21, 2021: Increased physical activity after ICD implantation linked to less hospitalization, death
    • Jul 14, 2021: Nihon Kohden Announces its Consolidated Financial Forecast for the First Quarter of Fiscal 2021
    • Jun 25, 2021: Japan Lifeline Notice of Resolution of the 41st Annual General Meeting of Shareholders
    • May 24, 2021: Boston Scientific to Participate in Bernstein's 37th Annual Strategic Decisions Conference
    • May 14, 2021: Fukuda Denshi announces Financial Results for the Fiscal Year Ending March 2021
    • May 13, 2021: Nihon Kohden announces FY2020 consolidated financial results
    • May 12, 2021: JMS Announces Financial Results for the Fiscal Year Ended March 31, 2021
    • Apr 28, 2021: Nihon Kohden Announces Change in Directors
    • Apr 28, 2021: Fukuda Denshi announces full year consolidated earnings forecast for fiscal year ending march 2021
    • Apr 28, 2021: CONMED Announces First Quarter Financial Results
    • Apr 20, 2021: Biotronik: Experts Make the Case for Improved Patient Care in Single-Chamber ICD and CRT-D Therapy with Pioneering DX Technology
    • Apr 15, 2021: Nihon Kohden Announces a Revision to its Forecast for Financial Results
    • Apr 01, 2021: CONMED to Announce First Quarter 2021 Financial Results on April 28, 2021
    • Mar 26, 2021: Philips' Announces Second-Quarter Results 2021
    • Mar 23, 2021: CONMED Announces Annual Meeting of Stockholders
    • Mar 22, 2021: Philips convenes the 2021 Annual General Meeting of Shareholders
    • Methodology
    • About GlobalData
    • Contact Us
    • Disclaimer

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us